Literature DB >> 27960083

S63845, an MCL-1 Selective BH3 Mimetic: Another Arrow in Our Quiver.

Anthony Letai1.   

Abstract

A recent study reports a novel small molecule inhibitor of MCL-1 with efficacy in killing MCL-1-dependent cancer cells in vitro and in vivo. With the advent of S63845, the targeting of BCL-2, BCL-XL, and MCL-1 is now possible in vivo, but optimal clinical use is yet to be determined.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27960083     DOI： 10.1016/j.ccell.2016.11.016

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  14 in total

1.  Endolysosomal Targeting of Mitochondria Is Integral to BAX-Mediated Mitochondrial Permeabilization during Apoptosis Signaling.

Authors:  Tim Sen Wang; Isabelle Coppens; Anna Saorin; Nathan Ryan Brady; Anne Hamacher-Brady
Journal:  Dev Cell       Date:  2020-06-05       Impact factor: 12.270

Review 2.  Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins.

Authors:  Rumani Singh; Anthony Letai; Kristopher Sarosiek
Journal:  Nat Rev Mol Cell Biol       Date:  2019-03       Impact factor: 94.444

3.  Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells.

Authors:  Mariana Belén Vera; Olivia Morris-Hanon; Germán Ignacio Nogueiras; Luisina Belén Ripari; Myrian Inés Esquivel; Carolina Perez-Castro; Leonardo Romorini; Gustavo Emilio Sevlever; María Elida Scassa; Guillermo Agustín Videla-Richardson
Journal:  Sci Rep       Date:  2022-10-22       Impact factor: 4.996

4.  Design, Synthesis, and Structural Characterization of Lysine Covalent BH3 Peptides Targeting Mcl-1.

Authors:  Luca Gambini; Parima Udompholkul; Carlo Baggio; Aruljothi Muralidharan; Nikola Kenjić; Zahra Assar; J Jefferson P Perry; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2021-04-02       Impact factor: 7.446

5.  A Non-apoptotic Function of MCL-1 in Promoting Pluripotency and Modulating Mitochondrial Dynamics in Stem Cells.

Authors:  Megan L Rasmussen; Leigh A Kline; Kyungho P Park; Natalya A Ortolano; Alejandra I Romero-Morales; Christin C Anthony; Kathryn E Beckermann; Vivian Gama
Journal:  Stem Cell Reports       Date:  2018-02-08       Impact factor: 7.765

6.  CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.

Authors:  Smit Kour; Sandeep Rana; Jacob I Contreras; Hannah M King; Caroline M Robb; Yogesh A Sonawane; Mourad Bendjennat; Ayrianne J Crawford; Carter J Barger; Smitha Kizhake; Xu Luo; Michael A Hollingsworth; Amarnath Natarajan
Journal:  Mol Pharmacol       Date:  2019-10       Impact factor: 4.436

7.  Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.

Authors:  Suresh Chava; Suresh Bugide; Yvonne J K Edwards; Romi Gupta
Journal:  Oncogenesis       Date:  2021-07-12       Impact factor: 7.485

8.  Demethylzeylasteral inhibits cell proliferation and induces apoptosis through suppressing MCL1 in melanoma cells.

Authors:  Yuzu Zhao; Jiang He; Jun Li; Xingzhi Peng; Xianxing Wang; Zhen Dong; Erhu Zhao; Yaling Liu; Zonghui Wu; Hongjuan Cui
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

Review 9.  Why do BCL-2 inhibitors work and where should we use them in the clinic?

Authors:  Joan Montero; Antony Letai
Journal:  Cell Death Differ       Date:  2017-10-27       Impact factor: 15.828

10.  Combination therapy with protein kinase inhibitor H89 and Tetrandrine elicits enhanced synergistic antitumor efficacy.

Authors:  Man Yu; Ting Liu; Yicheng Chen; Yafang Li; Wenhua Li
Journal:  J Exp Clin Cancer Res       Date:  2018-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.